ArticleAmerican journal of translational research2025
Plasma glial fibrillary acidic protein as a biomarker of blood-brain barrier integrity in patients with occult cerebral small vessel disease.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Plasma GFAP and NLRP3 Associate with Cognitive Impairment After Recent Small Subcortical Infarct via Periventricular White Matter Hyperintensity.CNS neuroscience & therapeutics · 2026Article
- Astrocyte-blood-brain barrier crosstalk in cerebral small vessel disease: linking barrier dysfunction to neurovascular failure.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the association between plasma glial fibrillary acidic protein (GFAP) levels and blood-brain barrier (BBB) integrity in patients with occult cerebral small vessel disease (CSVD).
methodsThis retrospective study included patients with occult CSVD (CSVD group, n = 68) and age-matched individuals without CSVD (control group, n = 61). Demographic and clinical characteristics were compared between groups. Cognitive function was assessed using the Montreal Cognitive Assessment-B (MoCA-B). Plasma GFAP levels were measured, and all participants underwent sequential magnetic resonance imaging (MRI) to evaluate BBB integrity. Patients were stratified based on total MRI burden of CSVD into moderate/severe and none/mild load groups. Risk factors associated with moderate/severe CSVD load were analyzed.
resultsThe prevalence of hyperlipidemia was significantly higher in the CSVD group than in the control group (P = 0.020), and MoCA-B scores were significantly lower. In the CSVD group, plasma GFAP levels were negatively correlated with total cholesterol (r = -0.281, P = 0.020) and low-density lipoprotein (r = -0.282, P = 0.020), as well as with MoCA-B scores (r = -0.440, P = 0.0002). MRI analysis revealed that brain regions showing significant correlations with elevated plasma GFAP levels exhibited BBB disruption and cortical thinning.
conclusionElevated plasma GFAP levels are associated with cognitive impairment and BBB disruption in patients with occult CSVD. GFAP may serve as a potential biomarker for evaluating BBB integrity in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.